FEXOFENADINE HYDROCHLORIDE HIVES
Clinical safety rating: safe
Aluminum and magnesium-containing antacids decrease absorption Rarely may cause headache or drowsiness.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
| Metabolism | Fexofenadine is not extensively metabolized; about 5% is metabolized by the gastrointestinal tract. It is a substrate for P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). |
| Excretion | Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%). |
| Half-life | Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief. |
| Protein binding | 60–70% bound to plasma proteins, primarily albumin (60%) and alpha-1-acid glycoprotein (10%). |
| Volume of Distribution | Volume of distribution is 3.0–4.0 L/kg, indicating extensive tissue distribution (extravascular binding). |
| Bioavailability | Oral bioavailability is approximately 30–35% (mean 33%) due to incomplete absorption and presystemic metabolism in the gut wall. No significant first-pass hepatic metabolism. |
| Onset of Action | Oral administration: Onset of action occurs within 1 hour for symptom relief (e.g., reduction in sneezing, rhinorrhea). |
| Duration of Action | Duration of action is approximately 24 hours based on symptom control, allowing once-daily dosing. However, histamine-induced wheal and flare suppression lasts up to 24 hours. |
60 mg orally twice daily or 180 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | For GFR <30 mL/min/1.73 m2: 60 mg orally once daily |
| Liver impairment | No dosage adjustment required for hepatic impairment |
| Pediatric use | 2-11 years (≥10 kg): 30 mg orally twice daily; 6 months to <2 years: 15 mg orally twice daily |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential decreased renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Aluminum and magnesium-containing antacids decrease absorption Rarely may cause headache or drowsiness.
| FDA category | Animal |
| Breastfeeding | Excreted into breast milk; M/P ratio not available. Use with caution in nursing mothers; monitor infant for drowsiness. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: No adequate studies; animal studies show no teratogenicity at up to 100 mg/kg/day. Second/third trimester: No evidence of fetal harm in limited human data; risk cannot be ruled out. |
■ FDA Black Box Warning
None
| Common Effects | Headache Drowsiness Dizziness Nausea |
| Serious Effects |
["Hypersensitivity to fexofenadine or any of its components"]
| Precautions | ["Use with caution in patients with renal impairment (dose adjustment recommended)","May cause dizziness or drowsiness, though less sedating than first-generation antihistamines","Not effective in treating asthma or other lower respiratory tract symptoms","Avoid use with fruit juices (grapefruit, orange, apple) as they may decrease absorption"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal adverse effects (e.g., sedation). |
| Fertility Effects | No known adverse effects on fertility in animal studies at doses up to 100 mg/kg/day. |